ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 571,57
0,91%
Dow Jones
38 783,92
0,50%
DAX
18 068,21
0,26%
Brent Oil
83,445
1,61%
Bitcoin
66 616,47
-0,03%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cyclerion Therapeutics Inc (CYCN)

  7. Cyclerion Therapeutics Inc (CYCN) Actualités

CYCN

Cyclerion Therapeutics (CYCN)

Cyclerion Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CYCN
DateHeureSourceTitreSymboleSociété
14/06/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCNCyclerion Therapeutics Inc
07/05/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYCNCyclerion Therapeutics Inc
26/01/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYCNCyclerion Therapeutics Inc
11/12/202323h09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CYCNCyclerion Therapeutics Inc
07/12/202322h05Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:CYCNCyclerion Therapeutics Inc
04/12/202314h00GlobeNewswire Inc.Cyclerion Appoints Regina Graul, Ph.D., as PresidentNASDAQ:CYCNCyclerion Therapeutics Inc
01/12/202300h16GlobeNewswire Inc.Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge InnovatorNASDAQ:CYCNCyclerion Therapeutics Inc
31/07/202313h00GlobeNewswire Inc.Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion AssetsNASDAQ:CYCNCyclerion Therapeutics Inc
20/06/202322h56Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:CYCNCyclerion Therapeutics Inc
09/06/202323h24Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:CYCNCyclerion Therapeutics Inc
01/06/202322h08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYCNCyclerion Therapeutics Inc
01/06/202322h00GlobeNewswire Inc.Cyclerion Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:CYCNCyclerion Therapeutics Inc
23/05/202322h00Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:CYCNCyclerion Therapeutics Inc
15/05/202319h00GlobeNewswire Inc.Cyclerion Announces Reverse Stock SplitNASDAQ:CYCNCyclerion Therapeutics Inc
12/05/202312h05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CYCNCyclerion Therapeutics Inc
12/05/202300h00GlobeNewswire Inc.Cyclerion Announces Definitive Agreement for Zagociguat and CY3018NASDAQ:CYCNCyclerion Therapeutics Inc
12/05/202300h00GlobeNewswire Inc.Cyclerion Announces Corporate Updates and Q1 2023 Financial ResultsNASDAQ:CYCNCyclerion Therapeutics Inc
03/04/202313h30GlobeNewswire Inc.Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment AgreementNASDAQ:CYCNCyclerion Therapeutics Inc
27/03/202313h00GlobeNewswire Inc.Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial DiseasesNASDAQ:CYCNCyclerion Therapeutics Inc
22/03/202322h01Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:CYCNCyclerion Therapeutics Inc
22/03/202321h40GlobeNewswire Inc.Cyclerion Reports Corporate Update and Full Year 2022 Financial ResultsNASDAQ:CYCNCyclerion Therapeutics Inc
09/02/202316h02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CYCNCyclerion Therapeutics Inc
13/01/202322h31Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CYCNCyclerion Therapeutics Inc
22/11/202213h00GlobeNewswire Inc.Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The CompanyNASDAQ:CYCNCyclerion Therapeutics Inc
21/10/202223h14Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:CYCNCyclerion Therapeutics Inc
06/10/202214h00GlobeNewswire Inc.Cyclerion Announces Mitochondrial Disease-Focused Corporate StrategyNASDAQ:CYCNCyclerion Therapeutics Inc
10/08/202222h46Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CYCNCyclerion Therapeutics Inc
09/08/202222h00GlobeNewswire Inc.Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial ResultsNASDAQ:CYCNCyclerion Therapeutics Inc
28/07/202213h00GlobeNewswire Inc.Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)NASDAQ:CYCNCyclerion Therapeutics Inc
26/07/202222h34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CYCNCyclerion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CYCN

Dernières Valeurs Consultées

EU
VK
Vallourec
EU
ML
Michelin
NASDAQ
NVDA
NVIDIA
EU
RI
Pernod Ricard
COIN
ETHUSD
Ethereum
EU
ORA
Orange
NYSE
DIS
Walt Disney
EU
EN
Bouygues
EU
PX1
CAC 40
NASDAQ
MSFT
Microsoft
EU
DG
Vinci
EU
HO
Thales
EU
SGO
Cie de SaintGobain
NASDAQ
AMZN
Amazon.com
NASDAQ
AAPL
Apple
EU
VIV
Vivendi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés